Search

Drug Profiles Catalysts Company Profiles Impact Events Target
Indication Trials KOL Insight Special Reports All

Drug Impact Events

Date Lead
Company
Event Type Approval
Change
Approval
Likelihood
1/27/15 Amgen (AMGN) Kyprolis for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
1/26/15 Shire (SHPG) SHP609 for Mucopolysaccharidosis II (MPS II; Hunter Syndrome) Subscribers Only Subscribers Only Subscribers Only
1/26/15 Synageva (GEVA) SBC-103 for Mucopolysaccharidosis III (MPS III; Sanfilippo Syndrome) Subscribers Only Subscribers Only Subscribers Only
1/26/15 BioCryst (BCRX) BCX4161 for Hereditary Angioedema (HAE) Subscribers Only Subscribers Only Subscribers Only
1/23/15 Rockwell (RMTI) Triferic for Anemia Due to Chronic Renal Failure, Dialysis-Dependent Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

Expected
Date Range
Lead
Company
Drug Expected
Catalyst
Now - 01/28/15 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
Now - 01/28/15 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
Now - 01/28/15 Subscribers Only Subscribers Only Regulatory - Supplemental Approval (Europe)
Now - 01/28/15 Subscribers Only Subscribers Only Regulatory - Supplemental Filing (Europe)
Now - 01/28/15 Subscribers Only Subscribers Only Trial Data - Top-Line Results